Delphia Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $67M
Overview
Creating RNA-based medicines to target undruggable cancer pathways.
Oncology
Technology Platform
Proprietary RNA technology platform designed to silence or modulate expression of difficult-to-drug oncology targets.
Funding History
1Total raised:$67M
Venture$67M
Opportunities
High unmet need for therapies targeting transcription factors and other intracellular oncoproteins.
Risk Factors
Platform and delivery risks common to RNA therapeutics, including stability, specificity, and tumor penetration.
Competitive Landscape
Enters a competitive RNA therapeutics field with a specific focus on undruggable oncology targets.